IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies
Discussion
Rituximab is the preferred treatment in IgG4-ND patients with severe disease by effectively targeting the production of pathogenic IgG-4 antibodies. In contrast, IVIG is ineffective because it inhibits immunoinflammatory functions irrelevant to the mechanistic effects of IgG4 and contains IgG-1 idiotypes that cannot sufficiently neutralize or possibly catabolize IgG4. Controlled studies with anti-CD19/20 monoclonals that also activate FcRIIb may be more promising in treating IgG4-ND.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Dalakas, M. C. Tags: Autoimmune diseases Views [amp ] Reviews Source Type: research
More News: Autoimmune Disease | Brain | Brain Tumor | CIDP | Encephalitis | Gammagard Liquid | Glioma | Neurology | Privigen | Rituxan | Study